Biomm S.A (BIOM3) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.164x

Based on the latest financial reports, Biomm S.A (BIOM3) has a cash flow conversion efficiency ratio of -0.164x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$-46.72 Million ≈ $-9.17 Million USD) by net assets (R$284.10 Million ≈ $55.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Biomm S.A - Cash Flow Conversion Efficiency Trend (2006–2024)

This chart illustrates how Biomm S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Biomm S.A balance sheet liabilities for a breakdown of total debt and financial obligations.

Biomm S.A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Biomm S.A ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Kore Potash Plc
AU:KP2
-0.004x
OmniAb Inc.
NASDAQ:OABI
-0.035x
Microvision Inc
NASDAQ:MVIS
-0.277x
Southern Cross Media Group Ltd
AU:SXL
0.143x
Arqit Quantum Inc.
NASDAQ:ARQQ
-0.603x
C&C International Corp.
KQ:352480
0.045x
SOL-GEL TECHN. IS-10
F:4SG
N/A
Ndr Auto Components Limited
NSE:NDRAUTO
0.023x

Annual Cash Flow Conversion Efficiency for Biomm S.A (2006–2024)

The table below shows the annual cash flow conversion efficiency of Biomm S.A from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Biomm S.A (BIOM3) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 R$262.78 Million
≈ $51.56 Million
R$-91.84 Million
≈ $-18.02 Million
-0.350x +42.54%
2023-12-31 R$122.94 Million
≈ $24.12 Million
R$-74.78 Million
≈ $-14.67 Million
-0.608x -53.63%
2022-12-31 R$159.11 Million
≈ $31.22 Million
R$-63.00 Million
≈ $-12.36 Million
-0.396x +52.89%
2021-12-31 R$111.59 Million
≈ $21.90 Million
R$-93.78 Million
≈ $-18.40 Million
-0.840x -66.12%
2020-12-31 R$191.48 Million
≈ $37.57 Million
R$-96.87 Million
≈ $-19.01 Million
-0.506x -0.11%
2019-12-31 R$153.56 Million
≈ $30.13 Million
R$-77.61 Million
≈ $-15.23 Million
-0.505x -21.54%
2018-12-31 R$106.09 Million
≈ $20.82 Million
R$-44.12 Million
≈ $-8.66 Million
-0.416x +54.67%
2017-12-31 R$59.30 Million
≈ $11.64 Million
R$-54.41 Million
≈ $-10.68 Million
-0.917x -58.00%
2016-12-31 R$65.93 Million
≈ $12.94 Million
R$-38.28 Million
≈ $-7.51 Million
-0.581x -380.95%
2015-12-31 R$115.13 Million
≈ $22.59 Million
R$-13.90 Million
≈ $-2.73 Million
-0.121x +34.64%
2014-12-31 R$107.10 Million
≈ $21.02 Million
R$-19.78 Million
≈ $-3.88 Million
-0.185x -91.50%
2013-12-31 R$108.94 Million
≈ $21.38 Million
R$-10.51 Million
≈ $-2.06 Million
-0.096x -129.36%
2012-12-31 R$-22.00 Million
≈ $-4.32 Million
R$-7.23 Million
≈ $-1.42 Million
0.329x +61.48%
2011-12-31 R$-8.76 Million
≈ $-1.72 Million
R$-1.78 Million
≈ $-349.66K
0.203x -82.19%
2010-12-31 R$-4.06 Million
≈ $-796.84K
R$-4.64 Million
≈ $-910.45K
1.143x -99.77%
2009-12-31 R$-15.00K
≈ $-2.94K
R$-7.50 Million
≈ $-1.47 Million
499.733x +106719.64%
2008-12-31 R$-12.22 Million
≈ $-2.40 Million
R$-5.71 Million
≈ $-1.12 Million
0.468x -30.15%
2006-12-31 R$3.09 Million
≈ $606.12K
R$2.07 Million
≈ $405.98K
0.670x --

About Biomm S.A

SA:BIOM3 Brazil Biotechnology
Market Cap
$201.38 Million
R$1.03 Billion BRL
Market Cap Rank
#16508 Global
#162 in Brazil
Share Price
R$7.50
Change (1 day)
+2.04%
52-Week Range
R$5.90 - R$10.64
All Time High
R$23.65
About

Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more